摘要
目的研究米非司酮联合妈富隆对功能性子宫出血患者止血效果及黄体生成素(LH)、雌二醇(E2)、孕酮(P)、抑制促卵泡生成素(FSH)的影响。方法选取2018年7月至2019年6月高密市市立医院收治的54例功能性子宫出血患者,按照随机数字表法分为对照组(n=27)和研究组(n=27)。对照组使用米非司酮治疗,研究组则联合妈富隆治疗,2组均治疗3个月。比较2组临床疗效,治疗前后血清LH、E2、P、FSH水平,子宫内膜厚度以及治疗后止血效果。结果研究组的总有效率为96.30%,高于对照组的77.78%(P<0.05);与治疗前相比,治疗后2组血清LH、E2、P、FSH水平及子宫内膜厚度均降低,且研究组低于对照组(P<0.05);与对照组相比,研究组的控制出血时间及完全止血时间均明显缩短(P<0.05)。结论米非司酮联合妈富隆可通过调节功能性子宫出血患者的性激素水平,抑制子宫内膜增生,达到快速止血的效果。
Objective To study the effect of mifepristone combined with marvelon hemostasis and LH,E2,P and FSH in patients with functional uterine bleeding.Methods Totally 54 patients patients with functional uterine bleeding admitted to gaomi municipal hospital from July 2018 to June 2019 were selected and divided into control group(n=27)and study group(n=27)according to the random number table method.The control group was treated with mifepristone and the study group with marvelon.Both groups were treated for 3 months.The clinical efficacy of the two groups was compared,including serum levels of LH,E2,P and FSH,endometrial thickness and hemostasis after treatment.Results The total effective rate of the study group was 96.30%,which was higher than that of the control group 77.78%(P<0.05);compared with before treatment,serum LH,E2,P and FSH levels and endometrial thickness in the two groups decreased after treatment,and the study group was lower than the control group(P<0.05);compared with the control group,the bleeding control time and complete hemostasis time in the study group were significantly shortened(P<0.05).Conclusion Mifepristone combined with marvelon can inhibit endometrial hyperplasia and achieve rapid hemostasis by regulating the sex hormone level in patients with functional uterine bleeding.
作者
王优敏
禚立双
WANG Youmin;ZHUO Lishuang(Gaomi Municipal Hospital,Weifang,Shandong 261500,China;Gaomi People's Hospital,Weifang,Shandong 261500,China)
出处
《大医生》
2019年第24期126-128,共3页
Doctor
关键词
米非司酮
妈富隆
功能性子宫出血
黄体生成素
雌二醇
孕酮
促卵泡生成素
mifepristone
marvelon
functional uterine bleeding
luteinizing hormone
estradiol
progesterone
follicle stimulating hormone